User:Mr. Ibrahem/Procainamide

Mr. Ibrahem/Procainamide
Clinical data
Pronunciation	/proʊˈkeɪnəmaɪd/
Trade names	Pronestyl, Procan, Procanbid, others
AHFS/Drugs.com	Monograph
Routes of; administration	IV, IM, by mouth
Drug class	Antiarrhythmic
Legal status
Legal status	UK: POM (Prescription only);
Pharmacokinetic data
Bioavailability	85% (by mouth)
Protein binding	15 to 20%
Metabolism	Liver (CYP2D6-mediated)
Onset of action	Within 30 min
Elimination half-life	~2.5 to 4.5 hours
Excretion	Kidney
Identifiers
	IUPAC name 4-amino-N-(2-diethylaminoethyl) benzamide;
Chemical and physical data
Formula	C13H21N3O
Molar mass	235.331 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(c1ccc(N)cc1)NCCN(CC)CC;
	InChI InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17) ; Key:REQCZEXYDRLIBE-UHFFFAOYSA-N ;
	(verify)

Procainamide is a medication of the antiarrhythmic type.^[1] It is used to treat heart arrhythmias including ventricular tachycardia and atrial fibrillation when people are otherwise stable.^[1] Other uses have included malignant hyperthermia.^[1] It is generally given by injection into a vein or muscle.^[1] Onset is generally within 30 minutes.^[1]

Common side effects include low blood pressure, itchiness, fever, and angioedema.^[1] Other side effects effects may include bone marrow suppression and arrhythmias.^[1] It is believed to be safe in the later part of pregnancy.^[2] Use during breastfeeding is not recommended.^[2] It is classified as a Ia Vaughan Williams antiarrhythmic.^[1] How it works is not entirely clear by may involve sodium channel blocking in heart muscle cells.^[1]

Procainamide was approved for medical use in the United States in 1950.^[1] It is available as a generic medication.^[3] In the United Kingdom it is only available by special order.^[4]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o "Procainamide Monograph for Professionals". Drugs.com. Archived from the original on 20 January 2021. Retrieved 25 December 2020.
^ ^a ^b "Procainamide Use During Pregnancy". Drugs.com. Archived from the original on 2 December 2020. Retrieved 25 December 2020.
^ Nitzki-George, Diane (2003). Generic Alternatives to Prescription Drugs. Basic Health Publications, Inc. p. 882. ISBN 978-1-59120-098-7. Archived from the original on 2021-08-29. Retrieved 2020-12-25.
^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 108. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[AHFS2020-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o "Procainamide Monograph for Professionals". Drugs.com. Archived from the original on 20 January 2021. Retrieved 25 December 2020.

[Preg2020-2] "Procainamide Use During Pregnancy". Drugs.com. Archived from the original on 2 December 2020. Retrieved 25 December 2020.

[3] Nitzki-George, Diane (2003). Generic Alternatives to Prescription Drugs. Basic Health Publications, Inc. p. 882. ISBN 978-1-59120-098-7. Archived from the original on 2021-08-29. Retrieved 2020-12-25.

[BNF80-4] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 108. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[1]

[2]

[3]

[4]